A new study that examined the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer, could help guide drug-pricing strategies to reduce financial burdens and increase the number of patients who benefit from treatment.
news, journals and articles from all over the world.
A new study that examined the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer, could help guide drug-pricing strategies to reduce financial burdens and increase the number of patients who benefit from treatment.